Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Beta blockers--1997 update]

K Stoschitzky1, W Klein

  • 1Klinische Abteilung für Kardiologie, Medizinische Universitätsklinik Graz, Osterreich.

Wiener Klinische Wochenschrift
|April 11, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enantioselective analysis of R- and S-propafenone in plasma by HPLC applying column switching and liquid-liquid extraction.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2009
Same author

The acute coronary syndrome--pre-hospital diagnostic quality.

Resuscitation·2005
Same author

[Efficiency and safety of ACE-inhibiting imidapril in patients with essential hypertension].

Acta medica Austriaca·2002
Same author

Beta-blockers in chronic heart failure.

European heart journal·2002
Same author

Stereoselective effects of (R)- and (S)-carvedilol in humans.

Chirality·2001
Same author

Differing beta-blocking effects of carvedilol and metoprolol.

European journal of heart failure·2001
Same journal

[Vaccination of immunocompromised individuals: Expert opinion - update 2026].

Wiener klinische Wochenschrift·2026
Same journal

Systematic review of clinical evidence for Kneipp medicine.

Wiener klinische Wochenschrift·2026
Same journal

Pelvic resections in primary sarcomas : Surgical outcomes and survival analysis of 75 patients.

Wiener klinische Wochenschrift·2026
Same journal

Jungmediziner*innen am Start: 11. Workshop für den medizinischen Nachwuchs.

Wiener klinische Wochenschrift·2026
Same journal

Stellungnahme der ÖGP zur geplanten Gesetzesnovelle zum Nichtraucherschutzgesetz.

Wiener klinische Wochenschrift·2026
Same journal

MUW researcher of the month: Dr. Moritz Schaefer.

Wiener klinische Wochenschrift·2026
See all related articles

Beta blockers are experiencing a resurgence due to proven reductions in morbidity and mortality. These cost-effective cardiovascular drugs are now recommended for hypertension and coronary artery disease, even in heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Beta blockers have a long history as first-line treatments for cardiovascular and non-cardiovascular diseases.
  • Their use declined in the 1980s with increased use of calcium antagonists and ACE inhibitors, often without clear clinical advantages in hard endpoints.
  • Recent evidence highlights beta blockers' efficacy in reducing morbidity and mortality across various conditions.

Purpose of the Study:

  • To review the current evidence supporting the use of beta blockers.
  • To highlight the renewed appreciation for beta blockers in cardiovascular therapy.
  • To emphasize their role in managing hypertension, ischemic heart disease, and congestive heart failure.

Main Methods:

  • Review of clinical evidence and therapeutic guidelines.

Related Experiment Videos

  • Analysis of comparative studies on hard endpoints (morbidity and mortality).
  • Evaluation of safety profiles and cost-effectiveness.

    • Main Results:

    • Beta blockers demonstrate significant reductions in morbidity and mortality compared to other agents or placebo.
    • Congestive heart failure is now an indication, not a contraindication, for beta blocker use.
    • Previously suspected side effects have not been confirmed; cost-effectiveness is a key factor.

    Conclusions:

    • Beta blockers are the drugs of choice for arterial hypertension and coronary artery disease, especially post-myocardial infarction.
    • Contraindications are limited, and conditions like congestive heart failure, peripheral arterial disease, and diabetes mellitus are no longer absolute contraindications.
    • Physicians increasingly prioritize hard endpoints like reduced mortality over surrogate markers.